Trial intelligence / Profile preview

KEYMAKER-U02 Substudy 02A in PD-1 refractory melanoma

2023-506312-41-00Phase 2Completed

Sponsor: Merck & Co.
Start: Dec 2023
Modality: Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
Countries: 6

Overview

Phase 2, open-label trial of pembrolizumab, lenvatinib, quavonlimab, vibostolimab and tretinoin in melanoma (5 arms), sponsored by Merck & Co. Primary endpoints: Percentage of participants who experience an adverse event, Percentage of participants who discontinue study treatment due to an adverse event and 1 more. Started Dec 2023; status: completed.

Drugs

pembrolizumablenvatinibquavonlimabvibostolimabtretinoin

Conditions

melanoma

Beyond the preview

Go deeper on 2023-506312-41-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2023-506312-41-00.